Johnson & Johnson announces $1bn cell therapy manufacturing facility in Pennsylvania

Johnson & Johnson has announced it is investing more than $1bn investment in a next generation cell therapy manufacturing facility in Montgomery County, Pennsylvania.

This new facility will further expand the Company’s U.S. manufacturing capacity as it advances its industry leading portfolio and pipeline of transformational medicines for cancer, immune-mediated and neurological diseases.

“For 140 years, Johnson & Johnson has been a leading innovator in American healthcare, and we are honored to continue advancing that legacy in Pennsylvania,” said Joaquin Duato, Chairman and Chief Executive Officer of Johnson & Johnson. “By uniting scientific excellence with state-of-the-art manufacturing and strategic investment, and by working collaboratively with our communities, we are delivering for patients and creating significant opportunities for workers and families.”

In building this facility, Johnson & Johnson continues to invest in cutting-edge manufacturing processes and in training to develop a workforce skilled in advanced technologies that are shaping the future of medicine. It will support more than 500 skilled biomanufacturing jobs when fully operational and more than 4,000 construction jobs during site development.

“Pennsylvania is a powerhouse for innovation and manufacturing in the life sciences,” said Governor Josh Shapiro. “Just a few years ago we weren’t even on the field – but today we’re competing and winning. We’ve done it by creating the first economic development plan for Pennsylvania in 2 decades, and following through on it by cutting red tape, making strategic investments in key industries like the life sciences, and strengthening our workforce. That’s why companies like Johnson & Johnson are choosing to double down on their investments here in our Commonwealth – because they know we’ve got the strategy, the workforce, and the speed they need to succeed.”